Global Corporate Communications
150 Signet Drive
ON, M9L 1T9
Investment from SK Capital to support Apotex’s next phase of growth and continued innovation for patient affordability
NEW YORK, September 28,2022/BUSINESS WIRE - An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) announced today that it has reached an agreement to acquire Apotex Pharmaceutical Holdings Inc. (“Apotex” or the “Company”), a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines across all major therapeutic areas for patients around the world.
“Apotex is a dynamic, entrepreneurial company with a strong track record of success, underpinned by its diversified product portfolio, robust pipeline of new launches and iconic brand. We feel incredibly privileged to have the opportunity to support Apotex with our deep experience in the pharmaceutical sector as it continues to research, develop and produce safe and affordable medicines for patients in Canada, the United States and around the world,” said Aaron Davenport, Managing Director at SK Capital.
Jeff Watson, President and CEO of Apotex, said, “We are excited to work with SK Capital, whose industry expertise and resources will help grow our leadership in the market and maintain our focus on improving access to high-quality affordable medicines for millions of patients worldwide.”
Closing of the transaction is subject to the satisfaction of customary regulatory conditions.
Lead arrangers RBC Capital Markets, The Bank of Nova Scotia, HSBC and Truist Securities are providing committed financing in support of the transaction. RBC Capital Markets, Scotiabank, Jefferies LLC and Deutsche Bank Securities Inc. served as financial advisors to SK Capital and Kirkland & Ellis and McMillan LLP served as legal counsel.
Rothschild & Co served as financial advisor to Apotex and Davies Ward Phillips & Vineberg served as legal counsel.
About SK Capital
SK Capital is a private investment firm with a disciplined focus on the specialty materials, specialty chemicals, and pharmaceuticals sectors. The firm seeks to build strong and growing businesses that create substantial long-term economic value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately USD $16 billion annually, employs more than 20,000 people globally and operates 203 plants in 32 countries. The firm currently has approximately USD $6.6 billion of assets under management. For more information, please visit www.skcapitalpartners.com.
Apotex is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. Apotex employs nearly 8,000 people worldwide in manufacturing, R&D, and commercial operations. Apotex exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the United States, Mexico, and India. For more information visit: www.apotex.com.